The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study

Basit Öğe Kaydı
dc.contributor.authorBerber, Ilhami
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorTuglular, Tulin Firatli
dc.date.accessioned2019-10-04T06:48:38Z
dc.date.available2019-10-04T06:48:38Z
dc.date.issued2016
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of >= 60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment. Median overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of <2, increasing number of AZA cycles (>= 5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact. Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA.en_US
dc.identifier.citationBerber, I. Erkurt, MA. Tuglular, TF. (2016). The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study. Cilt:33. Sayı:4. 273-280 ss.en_US
dc.identifier.doi10.4274/tjh.2015.0203en_US
dc.identifier.endpage280en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue4en_US
dc.identifier.pmid27095141en_US
dc.identifier.scopus2-s2.0-85002374731en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage273en_US
dc.identifier.trdizinid209161en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.2015.0203
dc.identifier.urihttps://hdl.handle.net/11616/14490
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/209161
dc.identifier.volume33en_US
dc.identifier.wosWOS:000392282500002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos yayıncılık, erkan mor, molla guranı cad 21-1, fındıkzade, ıstanbul 34093, turkeyen_US
dc.relation.ispartofTurkısh journal of hematologyen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_US
dc.subjectConventıonal care regımensen_US
dc.subjectrısk myelodysplastıc syndromeen_US
dc.subjectınternatıonal workıng groupen_US
dc.subjectacute myelogenous leukemıaen_US
dc.subjectnewly-dıagnosed amlen_US
dc.subjectolder patıentsen_US
dc.subjectıntensıve chemotherapyen_US
dc.subjectresponse crıterıaen_US
dc.subjectageen_US
dc.subjectcytarabıneen_US
dc.titleThe Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Studyen_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu